Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 345.20
Change Today +3.50 / 1.02%
Volume 46.7K
CFBI On Other Exchanges
Symbol
Exchange
Tel Aviv
OTC US
NYSE Amex
As of 10:24 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

can fite biopharma ltd (CFBI) Snapshot

Open
$345.00
Previous Close
$341.70
Day High
$349.00
Day Low
$341.20
52 Week High
03/23/15 - $1,163
52 Week Low
08/24/15 - $285.00
Market Cap
73.6M
Average Volume 10 Days
64.4K
EPS TTM
$-1.08
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAN FITE BIOPHARMA LTD (CFBI)

can fite biopharma ltd (CFBI) Related Bloomberg News

View More Bloomberg News

can fite biopharma ltd (CFBI) Related Businessweek News

No Related Businessweek News Found

can fite biopharma ltd (CFBI) Details

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. It offers CF101, which has completed Phase II/III clinical trials for the treatment of psoriasis; completed Phase II clinical trials for the treatment of rheumatoid arthritis; completed Phase I clinical study for the treatment of osteoarthritis; and completed Phase I study for the treatment of uveitis, as well as is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension. The company also develops CF102 that conducts a Phase II study for treating HCC and HCV; and CF602, which is in pre-clinical trial for the treatment of inflammatory diseases. Can-Fite BioPharma Ltd. is headquartered in Petah-Tikva, Israel.

9 Employees
Last Reported Date: 03/27/15

can fite biopharma ltd (CFBI) Top Compensated Officers

Scientific Founder, Chief Executive Officer a...
Total Annual Compensation: 1.3M
Chief Operating & Financial Officer and Princ...
Total Annual Compensation: 962.0K
Compensation as of Fiscal Year 2014.

can fite biopharma ltd (CFBI) Key Developments

Seikagaku Corporation Announces Termination of License Agreement with Can-Fite BioPharma Ltd. for Therapeutic Agent for Rheumatoid Arthritis

Seikagaku Corporation announced that it has agreed to terminate the license agreement with Can-Fite BioPharma Ltd. regarding a low-molecular chemical compound adenosine A3 receptor agonist (development code: CF101 and SI-615 for Can-Fite and Seikagaku, respectively). The termination is to become effective on August 27, 2015.

Can-Fite Biopharma Ltd. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2015

Can-Fite BioPharma Ltd. reported consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenues of ILS 0.271 million. Operating loss was ILS 10.150 million compared to ILS 14.061 million a year ago. Loss attributable to equity holders of the company was of ILS 7.898 million or ILS 0.37 per basic and diluted share compared to ILS 12.014 million or ILS 0.71 per basic and diluted share a year ago. The decrease in net loss for the first half of 2015 was attributable mainly to a decrease in operating expenses.

Can-Fite Biopharma Ltd. Receives a Lawsuit Requesting Recognition of the Lawsuit as a Class Action

On June 29, 2015, Can-Fite BioPharma Ltd. received a lawsuit requesting recognition of this lawsuit as a class action. The lawsuit alleges, among other things, that the company misled the public with regard to disclosures concerning the efficacy of the company's drug candidate, CF101. The claimant alleges that he suffered personal damages of over ILS 73,000, while also claiming that the shareholders of the company suffered damages of approximately ILS 125 million. The company strongly believes the lawsuit and its allegations to be baseless and without merit, and will vigorously defend this action.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFBI:IT 345.20 +3.50

CFBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFBI.
View Industry Companies
 

Industry Analysis

CFBI

Industry Average

Valuation CFBI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAN FITE BIOPHARMA LTD, please visit www.canfite.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.